Co-Diagnostics (CODX) revenue and earnings history
Co-Diagnostics reported revenue of $622K for fiscal 2025 (year ended Dec 31, 2025), −84.1% on the year before, and net income of −$46.9M.
Over 8 years, from fiscal 2017 to fiscal 2025, revenue grew at a compound rate of +73.3% a year.
Revenue and net income, 10 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $622K−84.1% | −$50.2M | −$46.9M | −$29.1M | $700K | −$29.8M | $2.25M | — | — | $11.9M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Co-Diagnostics (CODX) on OQRO.
Common questions
What was Co-Diagnostics's revenue in fiscal 2025?
$622K for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 31, 2026. That is −84.1% on fiscal 2024 ($3.92M).
How fast has Co-Diagnostics's revenue grown?
From $7.7K in fiscal 2017 to $622K in fiscal 2025: a compound annual growth rate of +73.3% over 8 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Co-Diagnostics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.